US EditionSartorius returns to a path of profitable growth in 2025 - European Biotechnology Magazine
4 Articles
4 Articles
Paypal misses expectations +++ US pharmaceutical company Merck corrects outlook down +++ Nintendo misses winning expectations despite switch-2 sales +++ The newsblog.
Sartorius returns to a path of profitable growth in 2025 - European Biotechnology Magazine
The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant exchange rates to around EUR 3.54 billion, while the operating EBITDA margin rose by 1.7 percentage points to 29.7%. The post Sartorius returns to a path of profitable growth in 2025 appeared first on European Biotechnology Magazine.
The manufacturer of consumables and equipment for the health sector anticipates a 6% growth this year if market conditions deteriorate.
Thanks to strong demand for consumables, Sartorius was able to significantly increase its profit in 2025, which makes the Group optimistic about the current year.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
